Pfizer drops after reverse turnaround in Q2

Pfizer shed 4.26% to Rs 1,633 at 10:23 IST on BSE after the company reported net loss of Rs 11.83 crore in Q2 September 2014 as against net profit of Rs 69.59 crore in Q2 September 2013.

The Q2 result was announced yesterday, 6 November 2014, when the stock market was closed on account of Gurunanak Jayanti.

Meanwhile, the S&P BSE Sensex was down 41.65 points or 0.15% at 27,874.23.

On BSE, so far 7,801 shares were traded in the counter as against average daily volume of 5,469 shares in the past one quarter.

The stock hit a high of Rs 1,675 and a low of Rs 1,618.75 so far during the day. The stock had hit a record high of Rs 1,824 on 16 September 2014. The stock had hit a 52-week low of Rs 1,020 on 3 February 2014.

The stock had underperformed the market over the past one month till 5 November 2014, advancing 3.13% compared with the Sensex's 5.07% rise. The scrip had, however, outperformed the market in past one quarter, jumping 27.96% as against Sensex's 7.75% rise.

The mid-cap company has equity capital of Rs 29.84 crore. Face value per share is Rs 10.

Pfizer's total income from operations declined 0.83% to Rs 296.48 crore in Q2 September 2014 over Q2 September 2013.

The company reported an exceptional expenditure of Rs 76.03 crore during Q2 September 2014 that include expenses in relation to Thane plant. The expenses include amount paid towards voluntary retirement scheme/other related costs.

Pfizer's pharmaceuticals product portfolio spans a wide range of therapeutic classes from vitamins supplements and nutritional to antibiotics and cardiovascular.

Powered by Capital Market - Live News